Giuseppe Curigliano, MD PhD, is Full Professor of Medical Oncology at the University of Milano and of
the Clinical Division of Early Drug Development at European Institute of Oncology, Milano, Italy. Dr.
Curigliano is an expert in the field of advanced drug development in solid tumors, with specific interest
on breast cancer. Its clinical activity is based on the genetic characterization of tumors and on testing
new experimental drugs specific for particular groups of patients. He contributed to the development of
many anticancer treatments actually available as standard of care in the treatment of multiple solid
tumors. Since 2001 he is tenure-track and full-time cancer specialist at European Institute of Oncology
– one of the world’s leading cancer-research institutes and the premier Cancer Center in Italy and third
in Europe. He serves as member of the Italian Higher Council Health. Dr. Curigliano serves ESMO as
Chair of the Clinical Practice Guidelines Committee. He was awarded with the first ESO Umberto
Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer
Sciences in Paris in 2017. Dr Curigliano in 2022 was identified as ClarivateTM world’s most influential
researchers. In 2022 the list identified fewer than 7,000, or about 0.1%, of the world's researchers, in 21
research fields and across multiple fields, have earned this exclusive distinction. Dr Curigliano has
contributed to over 590 peer-reviewed publications.